Shree Ganesh Remedies Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
671.00 -27.90 (-3.99%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
660
Today’s High
700.1
52 Week Low
557.95
52 Week High
950.05
Key Metrics
- Market Cap (In Cr) 897.89
- Beta 1.11
- Div. Yield (%) 0
- P/B 7.35
- TTM P/E 37.51
- Peg Ratio 0.76
- Sector P/E 31.15
- D/E 0.25
- Open Price 700
- Prev Close 698.9
Shree Ganesh Remedies Analysis
Price Analysis
-
1 Week-7.92%
-
3 Months-3.04%
-
6 Month14.2%
-
YTD2.37%
-
1 Year10.64%
Risk Meter
- 52% Low risk
- 52% Moderate risk
- 52% Balanced Risk
- 52% High risk
- 52% Extreme risk
Shree Ganesh Remedies News
Q3 Results Today: ZEEL, HAL, GlaxoSmithKline Pharma and more to post earnings
2 min read . 12 Feb 2024Stocks to Watch: RIL, Future Retail, PNB Housing Finance, Dr Reddy's
2 min read . 13 Jul 2021Shree Ganesh Remedies Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 125.9
- Selling/ General/ Admin Expenses Total
- 8.41
- Depreciation/ Amortization
- 6.11
- Other Operating Expenses Total
- 18.23
- Total Operating Expense
- 90.19
- Operating Income
- 35.7
- Net Income Before Taxes
- 38.16
- Net Income
- 28.11
- Diluted Normalized EPS
- 22.34
- Period
- 2024
- Total Assets
- 170.94
- Total Liabilities
- 48.84
- Total Equity
- 122.1
- Tangible Book Valueper Share Common Eq
- 94.75
- Period
- 2024
- Cashfrom Operating Activities
- 30.45
- Cashfrom Investing Activities
- -33.01
- Cashfrom Financing Activities
- 9.84
- Net Changein Cash
- 7.2
- Period
- 2023
- Total Revenue
- 90.22
- Selling/ General/ Admin Expenses Total
- 5.87
- Depreciation/ Amortization
- 3.72
- Other Operating Expenses Total
- 13.95
- Total Operating Expense
- 70.68
- Operating Income
- 19.54
- Net Income Before Taxes
- 22.58
- Net Income
- 17.02
- Diluted Normalized EPS
- 13.86
- Period
- 2023
- Total Assets
- 143.83
- Total Liabilities
- 54.9
- Total Equity
- 88.94
- Tangible Book Valueper Share Common Eq
- 73.62
- Period
- 2023
- Cashfrom Operating Activities
- 17.01
- Cashfrom Investing Activities
- -53.57
- Cashfrom Financing Activities
- 41.33
- Net Changein Cash
- 4.77
- Period
- 2022
- Total Revenue
- 71.29
- Selling/ General/ Admin Expenses Total
- 4.73
- Depreciation/ Amortization
- 3.34
- Other Operating Expenses Total
- 11.61
- Total Operating Expense
- 56.71
- Operating Income
- 14.58
- Net Income Before Taxes
- 18.01
- Net Income
- 13.4
- Diluted Normalized EPS
- 10.64
- Period
- 2022
- Total Assets
- 77.02
- Total Liabilities
- 15.44
- Total Equity
- 61.57
- Tangible Book Valueper Share Common Eq
- 48.53
- Period
- 2022
- Cashfrom Operating Activities
- 13.42
- Cashfrom Investing Activities
- -11.91
- Cashfrom Financing Activities
- -1.69
- Net Changein Cash
- -0.18
- Period
- 2021
- Total Revenue
- 49.08
- Selling/ General/ Admin Expenses Total
- 3.85
- Depreciation/ Amortization
- 2.73
- Other Operating Expenses Total
- 9.57
- Total Operating Expense
- 38.16
- Operating Income
- 10.92
- Net Income Before Taxes
- 12.95
- Net Income
- 9.75
- Diluted Normalized EPS
- 7.75
- Period
- 2021
- Total Assets
- 60.6
- Total Liabilities
- 10.59
- Total Equity
- 50
- Tangible Book Valueper Share Common Eq
- 47.07
- Period
- 2021
- Cashfrom Operating Activities
- 3.31
- Cashfrom Investing Activities
- -0.94
- Cashfrom Financing Activities
- -0.66
- Net Changein Cash
- 1.71
- Period
- 2020
- Total Revenue
- 58.43
- Selling/ General/ Admin Expenses Total
- 3.26
- Depreciation/ Amortization
- 2.24
- Other Operating Expenses Total
- 8.62
- Total Operating Expense
- 49.72
- Operating Income
- 8.71
- Net Income Before Taxes
- 12.74
- Net Income
- 9.62
- Diluted Normalized EPS
- 7.64
- Period
- 2020
- Total Assets
- 55.28
- Total Liabilities
- 13.08
- Total Equity
- 42.2
- Tangible Book Valueper Share Common Eq
- 38.82
- Period
- 2020
- Cashfrom Operating Activities
- 3.88
- Cashfrom Investing Activities
- -2.91
- Cashfrom Financing Activities
- -0.21
- Net Changein Cash
- 0.76
- Period
- 2019
- Total Revenue
- 35.31
- Selling/ General/ Admin Expenses Total
- 2.11
- Depreciation/ Amortization
- 1.04
- Other Operating Expenses Total
- 5.97
- Total Operating Expense
- 27.61
- Operating Income
- 7.71
- Net Income Before Taxes
- 8.67
- Net Income
- 6.24
- Diluted Normalized EPS
- 5.94
- Period
- 2019
- Total Assets
- 41.34
- Total Liabilities
- 7.52
- Total Equity
- 33.82
- Tangible Book Valueper Share Common Eq
- 32.16
- Period
- 2019
- Cashfrom Operating Activities
- -5.55
- Cashfrom Investing Activities
- -0.08
- Cashfrom Financing Activities
- -0.18
- Net Changein Cash
- -5.8
- Period
- 2018
- Total Revenue
- 27.26
- Selling/ General/ Admin Expenses Total
- 2.37
- Depreciation/ Amortization
- 0.6
- Other Operating Expenses Total
- 4.79
- Total Operating Expense
- 22.67
- Operating Income
- 4.59
- Net Income Before Taxes
- 6.48
- Net Income
- 4.69
- Diluted Normalized EPS
- 5.25
- Period
- 2018
- Total Assets
- 35.62
- Total Liabilities
- 6.95
- Total Equity
- 28.67
- Tangible Book Valueper Share Common Eq
- 27.31
- Period
- 2018
- Cashfrom Operating Activities
- -0.91
- Cashfrom Investing Activities
- -3.45
- Cashfrom Financing Activities
- 8.14
- Net Changein Cash
- 3.78
- Period
- 2024-09-30
- Total Revenue
- 32.33
- Selling/ General/ Admin Expenses Total
- 2.41
- Depreciation/ Amortization
- 2.42
- Other Operating Expenses Total
- 5.37
- Total Operating Expense
- 23.45
- Operating Income
- 8.89
- Net Income Before Taxes
- 8.64
- Net Income
- 6.41
- Diluted Normalized EPS
- 4.97
- Period
- 2024-09-30
- Total Assets
- 178.3
- Total Liabilities
- 45.17
- Total Equity
- 133.14
- Tangible Book Valueper Share Common Eq
- 103.31
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 13.65
- Cashfrom Investing Activities
- -10.35
- Cashfrom Financing Activities
- -4.91
- Net Changein Cash
- -1.2
- Period
- 2024-06-30
- Total Revenue
- 24.78
- Selling/ General/ Admin Expenses Total
- 2.35
- Depreciation/ Amortization
- 2.02
- Other Operating Expenses Total
- 5.91
- Total Operating Expense
- 18.67
- Operating Income
- 6.11
- Net Income Before Taxes
- 6.33
- Net Income
- 4.65
- Diluted Normalized EPS
- 3.62
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 37.33
- Selling/ General/ Admin Expenses Total
- 2.82
- Depreciation/ Amortization
- 1.86
- Other Operating Expenses Total
- 4.52
- Total Operating Expense
- 22.26
- Operating Income
- 15.07
- Net Income Before Taxes
- 16.24
- Net Income
- 12.58
- Diluted Normalized EPS
- 10
- Period
- 2024-03-31
- Total Assets
- 170.94
- Total Liabilities
- 48.84
- Total Equity
- 122.1
- Tangible Book Valueper Share Common Eq
- 94.75
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 30.45
- Cashfrom Investing Activities
- -33.01
- Cashfrom Financing Activities
- 9.84
- Net Changein Cash
- 7.2
- Period
- 2023-12-31
- Total Revenue
- 27.97
- Selling/ General/ Admin Expenses Total
- 1.99
- Depreciation/ Amortization
- 1.88
- Other Operating Expenses Total
- 5.3
- Total Operating Expense
- 21.65
- Operating Income
- 6.33
- Net Income Before Taxes
- 7.42
- Net Income
- 4.8
- Diluted Normalized EPS
- 3.84
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 33.42
- Selling/ General/ Admin Expenses Total
- 1.94
- Depreciation/ Amortization
- 1.41
- Other Operating Expenses Total
- 4.25
- Total Operating Expense
- 25.6
- Operating Income
- 7.82
- Net Income Before Taxes
- 8.61
- Net Income
- 6.55
- Diluted Normalized EPS
- 5.32
- Period
- 2023-09-30
- Total Assets
- 155.91
- Total Liabilities
- 56.25
- Total Equity
- 99.67
- Tangible Book Valueper Share Common Eq
- 82.75
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 6.54
- Cashfrom Investing Activities
- -9.49
- Cashfrom Financing Activities
- 1.6
- Net Changein Cash
- -1.36
- Period
- 2023-06-30
- Total Revenue
- 26.72
- Selling/ General/ Admin Expenses Total
- 1.59
- Depreciation/ Amortization
- 1.02
- Other Operating Expenses Total
- 4.44
- Total Operating Expense
- 20.97
- Operating Income
- 5.75
- Net Income Before Taxes
- 6.47
- Net Income
- 4.75
- Diluted Normalized EPS
- 3.86
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 29.33
- Selling/ General/ Admin Expenses Total
- 1.57
- Depreciation/ Amortization
- 1.03
- Other Operating Expenses Total
- 3.98
- Total Operating Expense
- 22.04
- Operating Income
- 7.29
- Net Income Before Taxes
- 7.63
- Net Income
- 5.87
- Diluted Normalized EPS
- 5.17
- Period
- 2023-03-31
- Total Assets
- 143.83
- Total Liabilities
- 54.9
- Total Equity
- 88.94
- Tangible Book Valueper Share Common Eq
- 73.62
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 17.01
- Cashfrom Investing Activities
- -53.57
- Cashfrom Financing Activities
- 41.33
- Net Changein Cash
- 4.77
- Period
- 2022-12-31
- Total Revenue
- 21.99
- Selling/ General/ Admin Expenses Total
- 1.55
- Depreciation/ Amortization
- 0.97
- Other Operating Expenses Total
- 3.07
- Total Operating Expense
- 17.6
- Operating Income
- 4.4
- Net Income Before Taxes
- 5.77
- Net Income
- 4.35
- Diluted Normalized EPS
- 3.45
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Shree Ganesh Remedies Technical
Moving Average
SMA
- 5 Day712.64
- 10 Day751.08
- 20 Day765.07
- 50 Day805.85
- 100 Day807.46
- 300 Day744.31
Shree Ganesh Remedies Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Fermenbio
- 326.2
- -5
- -1.51
- 354.6
- 145
- 941.88
- Kwality Pharmaceuticals
- 866
- -4.8
- -0.55
- 961.15
- 340
- 898.58
- Shree Ganesh Remedies
- 671
- -27.9
- -3.99
- 950.05
- 557.95
- 862.05
- Nectar Lifesciences
- 34.2
- -0.69
- -1.98
- 56.39
- 25.02
- 766.97
- Wanbury
- 211
- -11
- -4.95
- 291
- 91
- 690.93
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Fermenbio
- -
- 3.31
- 1.52
- 1.05
- Kwality Pharmaceuticals
- 30.96
- 4.03
- 30.12
- 13.13
- Shree Ganesh Remedies
- 31.28
- 7.35
- 24.29
- 19.73
- Nectar Lifesciences
- 157.05
- 0.73
- -0.65
- -0.41
- Wanbury
- 24.51
- 26.31
- -
- 7.62
Shree Ganesh Remedies Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-Oct-24
- Quarterly Results
- 28-Sept-24
- Others
- 12-Aug-24
- Quarterly Results
- 01-Jun-24
- Audited Resutls
- 30-May-24
- Audited Results
- 12-Feb-24
- Quarterly Results
- 25-Jan-24
- Others
- 10-Nov-23
- Quarterly Results
- 31-Jul-23
- Quarterly Results
- 30-May-23
- Audited Results & Final Dividend
- Meeting Date
- Announced on
- Purpose
- 18-Sept-23
- 11-Aug-23
- AGM
- 28-Sept-22
- 12-Jul-22
- AGM
- 12-Mar-22
- 09-Feb-22
- POM
- -
- 07-Feb-24
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 31-May-23
- 07-Sept-23
- 07-Sept-23
- 0.5
- 06-May-22
- 16-Sept-22
- 15-Sept-22
- 0.5
- 03-May-21
- 11-Sept-21
- 08-Sept-21
- 1.75
- Announced on
- Record Date
- Ex-Bonus
- Description
- 18-Sept-21
- 02-Nov-21
- 01-Nov-21
- Bonus issue in the ratio of 1:5 @ Rs. 10/-
- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 19-Nov-21
- 03-Feb-23
- 03-Feb-23
- 7:100
- 10
- 215
- Rights issue of equity shares of Rs. 10/- in the ratio of 7:100 @ premium of Rs. 215/-.